المؤلفون: V. Petrov I., A. Amosov A., A. Gerasimenko S., O. Shatalova V., A. Ponomareva V., A. Akinchits N., I. Kulakova S., V. Gorbatenko S., В. Петров И., А. Амосов А., А. Герасименко С., О. Шаталова В., А. Пономарева В., А. Акинчиц Н., И. Кулакова С., В. Горбатенко С.

المساهمون: This review did not have external funding., Данный обзор не имел финансирования от сторонних организаций

المصدر: Pharmacy & Pharmacology; Том 8, № 6 (2020); 380-391 ; Фармация и фармакология; Том 8, № 6 (2020); 380-391 ; 2413-2241 ; 2307-9266 ; 10.19163/2307-9266-2020-8-6

مصطلحات موضوعية: SARS-CoV-2, "cytokine storm", pharmacotherapy for COVID-19, «цитокиновый шторм», фармакотерапия COVID-19

وصف الملف: application/pdf

Relation: https://www.pharmpharm.ru/jour/article/view/767/664; https://www.pharmpharm.ru/jour/article/view/767/665; Chen Y., Liu Q., Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis // J Med Virol. – 2020. – Vol.92. – No.4. – P. 418-423. DOI:10.1002/jmv.25681.; Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J., Wang G., Jiang R., Gao Z., Jin Q., Wang J., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // Lancet. – 2020. – Vol.395. – No.10223. – P.497-506. DOI:10.1016/S0140-6736(20)30183-5.; Tisoncik J.R., Korth M.J., Simmons C.P., Farrar J., Martin T.R., Katze M.G. Into the eye of the cytokine storm // Microbiol Mol Biol Rev. – 2012. – Vol. 76. – No.1. – P. 16-32. DOI:10.1128/MMBR.05015-11; Vaduganathan M., Vardeny O., Michel T., McMurray J.J.V., Pfeffer M.A., Solomon S.D. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19 // N Engl J Med. – 2020. – Vol. 382. – No.17. – P. 1653-1659. DOI:10.1056/NEJMsr2005760; Garvin M.R., Alvarez C., Miller J.I., Prates E.T., Walker A.M., Amos B.K., Mast A.E., Justice A., Aronow B., Jacobson D. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm // Elife. – 2020. – Vol.7. – No.9. - e59177. DOI:10.7554/eLife.59177; Pacurari M., Kafoury R., Tchounwou P.B., Ndebele K. The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling // Int J Inflam. – 2014. – Vol. 2014. - 689360. DOI:10.1155/2014/689360; Xu P., Sriramula S., Lazartigues E. ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good // Am J Physiol Regul Integr Comp Physiol. – 2011. – Vol.300. - No 4. – P.804-817. DOI:10.1152/ajpregu.00222.2010; Santos R.A., Ferreira A.J., Verano-Braga T., Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system // J Endocrinol. – 2013. – Vol.216. – No.2. – P. 1-17. DOI:10.1530/JOE-12-0341; Xu X., Cui L., Hou F., Liu X., Wang Y., Wen Y., Chi C., Li C., Liu R., Yin C. Angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis prevents pancreatic acinar cell inflammatory response via inhibition of the p38 mitogen-activated protein kinase/nuclear factor-κB pathway // Int J Mol Med. – 2018. – Vol. 41. – No. 1. – P. 409-420. DOI:10.3892/ijmm.2017.3252; Magalhães G.S., Rodrigues-Machado M.G., Motta-Santos D., Silva A.R., Caliari M.V., Prata L.O., Abreu S.C., Rocco P.R., Barcelos L.S., Santos R.A., Campagnole-Santos M.J. Angiotensin-(1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation // Br J Pharmacol. – 2015. – Vol. 172. - No.9. – P. 2330-2342. DOI:10.1111/bph.13057; Chang C.F., D'Souza WN, Ch'en I.L., Pages G., Pouyssegur J., Hedrick S.M. Polar opposites: Erk direction of CD4 T cell subsets // J Immunol. – 2012. – Vol. 189. – No.2. – P. 721-731. DOI:10.4049/jimmunol.1103015; Mosmann T.R., Kobie J.J., Lee F.E., Quataert S.A. T helper cytokine patterns: defined subsets, random expression, and external modulation // Immunol Res. – 2009. – Vol. 45. – No. 2-3. – P. 173-184. DOI:10.1007/s12026-009-8098-5; Guilliams M., Movahedi K., Bosschaerts T., VandenDriessche T., Chuah M.K., Hérin M., Acosta-Sanchez A., Ma L., Moser M., Van Ginderachter J.A., Brys L., De Baetselier P., Beschin A. IL-10 dampens TNF/inducible nitric oxide synthase-producing dendritic cell-mediated pathogenicity during parasitic infection // J Immunol. – 2009. – Vol.182. –No.2. –P. 1107-1118. DOI:10.4049/jimmunol.182.2.1107; Soto M., diZerega G., Rodgers K.E. Countermeasure and therapeutic: A(1-7) to treat acute respiratory distress syndrome due to COVID-19 infection // J Renin Angiotensin Aldosterone Syst. – 2020. – Vol.21. – No.4. – 1470320320972018. DOI:10.1177/1470320320972018; Liu Y., Yang Y., Zhang C., Huang F., Wang F., Yuan J., Wang Z., Li J., Li J., Feng C., Zhang Z., Wang L., Peng L., Chen L., Qin Y., Zhao D., Tan S., Yin L., Xu J., Zhou C., Jiang C., Liu L. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury // Sci China Life Sci. – 2020. – Vol.63. – No.3. – P. 364-374. DOI:10.1007/s11427-020-1643-8; Pirola C.J., Sookoian S. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis // J Infect. – 2020. – Vol. 81. – No.2. – P. 276-281. DOI:10.1016/j.jinf.2020.05.052; Cheng H., Wang Y., Wang G.Q. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19 // J Med Virol. – 2020. – Vol.92. – No.7. – P.726-730. DOI:10.1002/jmv.25785; Sodhi C.P., Wohlford-Lenane C., Yamaguchi Y., Prindle T., Fulton W.B., Wang S., McCray P.B. Jr., Chappell M., Hackam D.J., Jia H. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration // Am J Physiol Lung Cell Mol Physiol. – 2018. – Vol.314. – No.1. – P. 17-31. DOI:10.1152/ajplung.00498.2016; Erdös E.G., Jackman H.L., Brovkovych V., Tan F., Deddish P.A. Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin // J Mol Cell Cardiol. – 2002. – Vol. 34. – No.12. – P. 1569-1576. DOI:10.1006/jmcc.2002.2080; Kaplan A.P., Ghebrehiwet B. The plasma bradykinin-forming pathways and its interrelationships with complement // Mol Immunol. – 2010. – Vol. 47. – No.13. – P. 2161-2169. DOI:10.1016/j.molimm.2010.05.010; Gao T., Hu M., Zhang X., et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation // medRxiv. – 2020.03.29.20041962 DOI:10.1101/2020.03.29.20041962; Dobó J., Kocsis A., Gál P. Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases // Front Immunol. – 2018. – Vol. 8. – No. 9. – P. 1851. DOI:10.3389/fimmu.2018.01851; Schindler R., Gelfand J.A., Dinarello C.A. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself // Blood. – 1990. – Vol.76. – No. 8. – P. 1631-1638.; Viedt C., Hänsch G.M., Brandes R.P., Kübler W., Kreuzer J. The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1 // FASEB J. – 2000. – Vol. 14. – No.15. – P. 2370-2372. DOI:10.1096/fj.00-0468fje; Torzewski J., Oldroyd R., Lachmann P., Fitzsimmons C., Proudfoot D., Bowyer D. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation // Arterioscler Thromb Vasc Biol. – 1996. – Vol. 16. –No. 5. – P. 673-677. DOI:10.1161/01.atv.16.5.673; Laudisi F., Spreafico R., Evrard M., Hughes T.R., Mandriani B., Kandasamy M., Morgan B.P., Sivasankar B., Mortellaro A. Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release // J Immunol. – 2013. – Vol. 191. – No. 3. – P. 1006-1010. DOI:10.4049/jimmunol.1300489; Rambaldi A., Gritti G., Micò M.C., Frigeni M., Borleri G., Salvi A., Landi F., Pavoni C., Sonzogni A., Gianatti A., Binda F., Fagiuoli S., Di Marco F., Lorini L., Remuzzi G., Whitaker S., Demopulos G. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab // Immunobiology. – 2020. – Vol. 225. – No. 6. DOI:10.1016/j.imbio.2020.152001; Gralinski L.E., Sheahan T.P., Morrison T.E., Menachery V.D., Jensen K., Leist S.R., Whitmore A., Heise M.T., Baric R.S. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis // mBio. – 2018. – Vol. 9. – No. 5. – P. e01753-18 DOI:10.1128/mBio.01753-18; Kaneiwa T., Mizumoto S., Sugahara K., Yamada S. Identification of human hyaluronidase-4 as a novel chondroitin sulfate hydrolase that preferentially cleaves the galactosaminidic linkage in the trisulfated tetrasaccharide sequence // Glycobiology. – 2010. – Vol. 20. – No. 3. – P. 300-309. DOI:10.1093/glycob/cwp174; Harada H., Takahashi M. CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2 // J Biol Chem. – 2007. – Vol. 282. – No.8. – P. 5597-5607. DOI:10.1074/jbc.M608358200; Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L., Tai Y., Bai C., Gao T., Song J., Xia P., Dong J., Zhao J., Wang F.S. Pathological findings of COVID-19 associated with acute respiratory distress syndrome // Lancet Respir Med. – 2020. – Vol. 8. – No. 4. – P. 420-422. DOI:10.1016/S2213-2600(20)30076-X; Hällgren R., Samuelsson T., Laurent T.C., Modig J. Accumulation of hyaluronan (hyaluronic acid) in the lung in adult respiratory distress syndrome // Am Rev Respir Dis. – 1989. – Vol. 139. – No.3. – P. 682-687. DOI:10.1164/ajrccm/139.3.682; Bell T.J., Brand O.J., Morgan D.J., Salek-Ardakani S., Jagger C., Fujimori T., Cholewa L., Tilakaratna V., Östling J., Thomas M., Day A.J., Snelgrove R.J., Hussell T. Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis // Matrix Biol. – 2019. – Vol. 80. – P. 14-28. DOI:10.1016/j.matbio.2018.06.006; Hellman U., Karlsson M.G., Engström-Laurent A., Cajander S., Dorofte L., Ahlm C., Laurent C., Blomberg A. Presence of hyaluronan in lung alveoli in severe Covid-19: An opening for new treatment options? // J Biol Chem. – 2020. – Vol.295. – No.45. – P. 15418-15422. DOI:10.1074/jbc.AC120.015967; Safari S., Salimi A., Zali A., Jahangirifard A., Bastanhagh E., Aminnejad R., Dabbagh A., Lotfi A.H., Saeidi M. Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Severe COVID-19 patients; a Narrative Review // Arch Acad Emerg Med. – 2020. – Vol. 8. – No.1.- P.e67.; Haschke M., Schuster M., Poglitsch M., Loibner H., Salzberg M., Bruggisser M., Penninger J., Krähenbühl S. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects // Clin Pharmacokinet. – 2013. – Vol. 52. – No. 9. – P. 783-792. DOI:10.1007/s40262-013-0072-7; Khan A., Benthin C., Zeno B., Albertson T.E., Boyd J., Christie J.D., Hall R., Poirier G., Ronco J.J., Tidswell M., Hardes K., Powley W.M., Wright T.J., Siederer S.K., Fairman D.A., Lipson D.A., Bayliffe A.I., Lazaar A.L. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome // Crit Care. – 2017. – Vol. 21. – No.1. – P. 234. DOI:10.1186/s13054-017-1823-x; Monteil V., Kwon H., Prado P., Hagelkrüys A., Wimmer R.A., Stahl M., Leopoldi A., Garreta E., Hurtado Del Pozo C., Prosper F., Romero J.P., Wirnsberger G., Zhang H., Slutsky A.S., Conder R., Montserrat N., Mirazimi A., Penninger J.M. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 // Cell. – 2020. – Vol.181. – No.4. – P. 905-913 DOI:10.1016/j.cell.2020.04.004; Peiró C., Moncada S. Substituting Angiotensin-(1-7) to Prevent Lung Damage in SARS-CoV-2 Infection? // Circulation. – 2020. – Vol. 141. – No.21. – P. 1665-1666. DOI:10.1161/CIRCULATIONAHA.120.047297; Grant W.B., Lahore H., McDonnell S.L., Baggerly C.A., French C.B., Aliano J.L., Bhattoa H.P. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths // Nutrients. – 2020. – Vol.12. – No.4. – P. 988. DOI:10.3390/nu12040988; Li Y.C., Qiao G., Uskokovic M., Xiang W., Zheng W., Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure // J Steroid Biochem Mol Biol. – 2004. – P. 387-392. DOI:10.1016/j.jsbmb.2004.03.004; Maghbooli Z., Sahraian M.A., Ebrahimi M., Pazoki M., Kafan S., Tabriz H.M., Hadadi A., Montazeri M., Nasiri M., Shirvani A., Holick M.F. Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection // PLoS One. – 2020. – Vol.15. – No.9. – P. e0239799. DOI:10.1371/journal.pone.0239799.; Rejnmark L., Bislev L.S., Cashman K.D., Eiríksdottir G., Gaksch M., Grübler M., Grimnes G., Gudnason V., Lips P., Pilz S., van Schoor N.M., Kiely M., Jorde R. Non-skeletal health effects of vitamin D supplementation: A systematic review on findings from meta-analyses summarizing trial data // PLoS One. – 2017. – V. 12. – No.7. – P. e0180512. DOI:10.1371/journal.pone.0180512; Martineau A.R., Jolliffe D.A., Hooper R.L., Greenberg L., Aloia J.F., Bergman P., Dubnov-Raz G., Esposito S., Ganmaa D., Ginde A.A., Goodall E.C., Grant C.C., Griffiths C.J., Janssens W., Laaksi I., Manaseki-Holland S., Mauger D., Murdoch D.R., Neale R., Rees J.R., Simpson S. Jr., Stelmach I., Kumar G.T., Urashima M., Camargo C.A. Jr.Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data // BMJ. – 2017. – Vol.356. – P.i6583. DOI:10.1136/bmj.i6583; Bozó É., Éles J., Keserű G.M. Bradykinin B1 receptor antagonists: a patent update 2009 – 2012 // Expert Opin Ther Pat. – 2012. – Vol. 22. – No.12. – P. 1443-1452. DOI:10.1517/13543776.2012.730521; Thomson T.M., Toscano E., Casis E., Paciucci R. C1-INH and the contact system in COVID-19 // Br J Haematol. 2020. – Vol. 190. – No.4. – P. 520-524. DOI:10.1111/bjh.16938.; Urwyler P., Moser S., Charitos P., Heijnen I.A.F.M., Rudin M., Sommer G., Giannetti B.M., Bassetti S., Sendi P., Trendelenburg M., Osthoff M. Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System // Front Immunol. – 2020. – Vol.11. – P.2072. DOI:10.3389/fimmu.2020.02072; van de Veerdonk F.L., Kouijzer I.J.E., de Nooijer A.H., van der Hoeven H.G., Maas C., Netea M.G., Brüggemann R.J.M. Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19 // JAMA Netw Open. – 2020. – Vol. 3. – No.8. DOI:10.1001/jamanetworkopen.2020.17708; Diurno F., Numis F.G., Porta G., Cirillo F., Maddaluno S., Ragozzino A., De Negri P., Di Gennaro C., Pagano A., Allegorico E, Bressy L, Bosso G, Ferrara A, Serra C, Montisci A, D'Amico M, Schiano Lo Morello S, Di Costanzo G, Tucci AG, Marchetti P., Di Vincenzo U., Sorrentino I., Casciotta A., Fusco M., Buonerba C., Berretta M., Ceccarelli M., Nunnari G., Diessa Y., Cicala S., Facchini G. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience // Eur Rev Med Pharmacol Sci. – 2020. – Vol. 24. – No.7. – P. 4040-4047. DOI:10.26355/eurrev_202004_20875; Mastellos D.C., Ricklin D., Lambris J.D. Clinical promise of next-generation complement therapeutics // Nat Rev Drug Discov. – 2019. – Vol.18. – No.9. – P. 707-729. DOI:10.1038/s41573-019-0031-6; Mastellos D.C., Pires da Silva B.G.P., Fonseca B.A.L., Fonseca N.P., Auxiliadora-Martins M., Mastaglio S., Ruggeri A., Sironi M., Radermacher P., Chrysanthopoulou A., Skendros P., Ritis K., Manfra I., Iacobelli S., Huber-Lang M., Nilsson B., Yancopoulou D., Connolly E.S., Garlanda C., Ciceri F., Risitano A.M., Calado R.T., Lambris J.D. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy // Clin Immunol. – 2020. – Vol.220. – P.108598. DOI:10.1016/j.clim.2020.108598; Wang X., Sahu K.K., Cerny J. Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19 // J Thromb Thrombolysis. – 2020. – Vol. 1-6. DOI:10.1007/s11239-020-02297-z; Shi Y., Wang Y., Shao C., Huang J., Gan J., Huang X., Bucci E., Piacentini M., Ippolito G., Melino G. COVID-19 infection: the perspectives on immune responses // Cell Death Differ. – 2020. – Vol. 27. – No.5. – P. 1451-1454. DOI:10.1038/s41418-020-0530-3; Kultti A., Pasonen-Seppänen S., Jauhiainen M., Rilla K.J., Kärnä R., Pyöriä E., Tammi R.H., Tammi M.I. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3 // Exp Cell Res. - 2009. – Vol. 315. – No.11. – P. 1914-1923. DOI:10.1016/j.yexcr.2009.03.002; Nasonov E., Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19 // Biomed Pharmacother. – 2020. – Vol.131. – P.110698. DOI:10.1016/j.biopha.2020.110698; Kaye A.G., Siegel R. The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review // PeerJ. – 2020. – Vol.2. – No.8. – P.e10322. DOI:10.7717/peerj.10322; Rafiullah M., Siddiqui K. Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019 // J Comp Eff Res. – 2020. – Vol. 9. – No.18. – P. 1247-1254. DOI:10.2217/cer-2020-0146; RECOVERY Collaborative Group; Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., Elmahi E., Prudon B., Green C., Felton T., Chadwick D., Rege K., Fegan C., Chappell L.C., Faust S.N., Jaki T., Jeffery K., Montgomery A., Rowan K., Juszczak E., Baillie J.K., Haynes R., Landray M.J. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report // N Engl J Med. – 2021. – Vol.384. – No.8. – P.693-704DOI: 10.1056/NEJMoa2021436; Maskin LP, Olarte GL, Palizas F Jr, Velo AE, Lurbet MF, Bonelli I, Baredes ND, Rodríguez PO. High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials. – 2020. – Vol. 21. – No.1. – P. 743. DOI:10.1186/s13063-020-04646-y; https://www.pharmpharm.ru/jour/article/view/767

الاتاحة: https://www.pharmpharm.ru/jour/article/view/767
https://doi.org/10.19163/2307-9266-2020-8-6-380-391